Short Treatment with Omalizumab for Severe Asthma

Inclusion Criteria: * Adult patient \>18 years old * Treated with OMA, prescribed by a pulmonologist , for at least 33 months for severe allergic asthma * Well controlled with the treatment (ACT score ⩾ 18) and having experienced no more than one exacerbation in the year preceding inclusion. An exacerbation is defined as an oral or injectable steroid course for at least 2 days and/or a minimum doubling of the usual steroid dose for at least 2 days for steroid dependent patients Exclusion Criteria: * Patient refusing to stop OMA treatment, whatever the reason * Patient with other reason other than good asthma control to stop OMA, such as a side effect, planned or ongoing pregnancy, or planned switch to another step 5 asthma treatment (mepolizumab, benralizumab, dupilumab, reslizumab, daily oral steroids, bronchial thermoplasty, …) * Patient not covered by Health Insurance * Patient under curatorship, guardianship or safeguarding of justice * Patient whose adherence to asthma treatments is considered poor or questionable by the investigator * Patient participating in another intervention research * Pregnant or lactating patient * Patient refusing to sign consent